BlackSalmon/iStock via Getty Images The AMG Boston Common Global Impact Fund (Class I) returned -0.80% for the first quarter of 2026, compared with -3.20% for the benchmark, the MSCI ACWI Index. For the 12 months ending March 31, 2026, the Fund returned 24.97%, while the benchmark returned 20.01%. Average Annual Returns (%) 2 (as of 03/31/26) Q1 YTD 1 Yr 3 Yr 5 Yr 10 Yr Since Inception 3 BRWIX (Cl...
BlackSalmon/iStock via Getty Images The AMG Boston Common Global Impact Fund (Class I) returned -0.80% for the first quarter of 2026, compared with -3.20% for the benchmark, the MSCI ACWI Index. For the 12 months ending March 31, 2026, the Fund returned 24.97%, while the benchmark returned 20.01%. Average Annual Returns (%) 2 (as of 03/31/26) Q1 YTD 1 Yr 3 Yr 5 Yr 10 Yr Since Inception 3 BRWIX (Class I) -0.80 -0.80 24.97 8.90 2.94 10.25 9.86 MSCI ACWI Index 4 -3.20 -3.20 20.01 16.58 9.49 11.34 — Click to enlarge BRWIX (Class I) Expense Ratio (Gross/Net) 5 : 0.95%/0.93% 1 Prior to March 19, 2021, the Fund was known as the AMG Managers Brandywine Fund, and had different principal investment strategies and corresponding risks. Performance shown for periods prior to March 19, 2021, reflects the performance and investment strategies of the Fund's previous subadvisor, Friess Associates, LLC and Friess Associates of Delaware, LLC. The Fund's past performance would have been different if the Fund were managed by the current subadvisor and strategy, and the Fund's prior performance record might be less pertinent for investors considering whether to purchase shares of the fund. 2 Returns for periods less than one year are not annualized. 3 Since the inception of the Fund on December 30, 1985. 4 On March 19, 2021, the benchmark changed from the Russell 3000 ® Growth Index to MSCI All Country World Index. 5 The Fund's Investment Manager has contractually agreed, through February 1, 2027, to limit fund operating expenses. The net expense ratio reflects this limitation, while the gross expense ratio does not. The Fund has no up-front sales charges or deferred sales charges. Please refer to the Fund's Prospectus for additional information on the Fund's expenses. The performance data shown represents past performance. Past performance is not a guarantee of future results. The investment return and the principal value of an investment will fluctuate so that an investor's shares, whe...
FinkAvenue/iStock Editorial via Getty Images Shares of medical technology concern GE HealthCare Technologies Inc. ( GEHC ) has fallen over the last month after reporting a 1Q26 miss at the bottom line that triggered a downward revision to its FY26 outlook. The quick and meaningful alteration to its forecast was caused by significant cost inflation, which is scheduled to be ~$250 million greater th...
FinkAvenue/iStock Editorial via Getty Images Shares of medical technology concern GE HealthCare Technologies Inc. ( GEHC ) has fallen over the last month after reporting a 1Q26 miss at the bottom line that triggered a downward revision to its FY26 outlook. The quick and meaningful alteration to its forecast was caused by significant cost inflation, which is scheduled to be ~$250 million greater than anticipated, led by memory chip and freight outlays. With no change to its top-line outlook and trading near three-year lows with a PE on FY26 non-GAAP earnings of 12.8, the recent selloff in this stock merited a deeper dive. An analysis follows below. GEHC Stock Chart (Seeking Alpha) Company Overview: GE HealthCare Technologies Inc. is a Chicago based provider of advanced medical technology, pharmaceutical diagnostics, AI and software solutions to hospitals, health systems, and research institutions in over 160 countries. With roots dating back to 1893, GE Healthcare was formed as a subsidiary of General Electric ( GE ) in 1994 and was spun out in 2023, with its first ' when-issued ' trade executed at $63.00 per share (in December 2022). Its stock currently trades just over $62.00 a share and sports an approximate market capitalization of just over $28 billion. Operating Segments The company views its performance through four operating segments: Imaging, Advanced Visualization Solutions [AVS], Patient Care Solutions [PCS], and Pharmaceutical Diagnostics (PDx). Imaging . GE Healthcare's largest segment (45% of total FY25 revenue) is Imaging, which consists primarily of five product lines: Molecular Imaging (cyclotrons, tomography, nuclear medicine); Computed Tomography (3D images from a rotating X-ray tube), Magnetic Resonance (MRIs), Women's Health (breast scans), and X-ray. It contributed FY25 EBIT of $891 million on revenue of $9.25 billion versus EBIT of $962 million on revenue of $8.86 billion in FY24, representing a 7% decrease on a 4% increase at the top line. Tho...
Yuan Gujie A prominent legal expert has been named a deputy director of Beijing’s liaison office in Hong Kong, part of a broader reshuffle of officials with prestigious academic credentials in China’s government. Yuan Guijie, who previously served as the top security official in the neighboring southern Guangdong province, has been appointed deputy director of the Liaison Office of the Central Peo...
Yuan Gujie A prominent legal expert has been named a deputy director of Beijing’s liaison office in Hong Kong, part of a broader reshuffle of officials with prestigious academic credentials in China’s government. Yuan Guijie, who previously served as the top security official in the neighboring southern Guangdong province, has been appointed deputy director of the Liaison Office of the Central People’s Government in the Hong Kong Special Administrative Region, according to a government notice on Monday.Yuan, 58, will rank second among the office’s four deputy directors.
FabrikaCr/iStock via Getty Images While Applied Materials Inc. ( AMAT ) has long been one of the world's leading suppliers of semiconductor equipment, the emergence of AI infrastructure is creating another big opportunity for the company. Morgan Stanley upped its estimate of Applied Materials' price target after it reported another quarter of record revenue and earnings. Analysts feel that Applied...
FabrikaCr/iStock via Getty Images While Applied Materials Inc. ( AMAT ) has long been one of the world's leading suppliers of semiconductor equipment, the emergence of AI infrastructure is creating another big opportunity for the company. Morgan Stanley upped its estimate of Applied Materials' price target after it reported another quarter of record revenue and earnings. Analysts feel that Applied Materials could benefit from the rising demand for the advanced logic chips, DRAM memory, and advanced packaging technologies that can be leveraged by AI systems. Furthermore, management expects its semiconductor equipment segment to grow more than 30% in 2026, driven by ongoing growth in the semiconductor industry's investments in AI. Additionally, Applied Materials is diversifying its business from semiconductor equipment by making partnerships and research agreements related to next-generation AI chips. The company is working with four other companies to establish a new semiconductor research facility with capital of $125 million focused on AI technology and the development of future semiconductors. The goal is to bolster long-term U.S. semiconductor research, workforce and supply chain resilience. Collaborations such as these may enable Applied Materials to stay in step with future semiconductor design advancements and the changing needs of AI computing in the long run. Recent earnings also have been a positive boost to the company's near-term outlook. Applied Materials posted fiscal second-quarter revenues of $7.91 billion, up 11% from a year ago, and adjusted earnings of $2.86 per share, beating Wall Street estimates. The company also provided better than anticipated guidance for the current quarter, as semiconductor systems and AI-related demand continued to drive growth. Combined with Applied Materials' expertise in high-tech semiconductor technologies, the company has a solid basis for strong multi-year revenue and profit growth, according to CEO Gary Dickerson. S...
koto_feja/E+ via Getty Images I’ve written about IonQ, Inc. ( IONQ ) in the past, and the stock has gained quite a bit of attention recently, leading to a nice pop upward. Ever since my last article, the company has made a few technological improvements and seems to be getting some momentum revenue-wise. Consider this an update piece on why IonQ should still be considered for highly speculative in...
koto_feja/E+ via Getty Images I’ve written about IonQ, Inc. ( IONQ ) in the past, and the stock has gained quite a bit of attention recently, leading to a nice pop upward. Ever since my last article, the company has made a few technological improvements and seems to be getting some momentum revenue-wise. Consider this an update piece on why IonQ should still be considered for highly speculative investors. Quarterly Financials Analysis Analyzing the company’s most recent Q1 2026 results, it may seem at first glance that revenue is exploding. In the latest quarter, revenue grew by 755%, from $7.6 million to $64.7 million. Management has attributed this to strong global system sales, increasing Tempo demand, a stronger pipeline, and cloud utilization. While revenue growth should always be celebrated, I should point out that IonQ’s revenue was growing from a very small base. Data by YCharts There is cause for optimism, though, as for FY 2026, IonQ’s management has guided for revenues of around $260 million and $270 million. This is roughly double last year’s revenue, with Q2 2026 alone guided to be between $65 million and $68 million. Accelerating revenues show that there could be an underlying demand for IonQ’s quantum projects. Adjusted EBITDA loss grew from a loss of $34.1 million to a loss of $96.8 million despite the jump in revenues. Given this continued EBITDA loss and relatively small revenue vis-à-vis the company’s assets and market cap, investors should pay attention to the state of its balance sheet. The good news is the company is debt-free, although it has $2.47 billion in warrant liabilities. Total liabilities fell 38%, from $2.76 billion to $1.7 billion. IonQ has a decent cash liquidity position with cash of $493.5 million. Including equivalents and investments, this is about $3.1 billion. With a full-year adjusted EBITDA loss guidance of ($330) million and ($310) million, this implies a cash burn rate of 7.94 years. Plenty of liquidity room for the compa...